Vanguard Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.6M Buy
2,140,758
+41,703
+2% +$543K ﹤0.01% 2167
2026
Q2
$27.9M Sell
2,099,055
-96,523
-4% -$940K ﹤0.01% 2270
2026
Q1
$20.4M Buy
+2,195,578
New +$19.1M ﹤0.01% 2336

Other funds holding FDMT

Vanguard Capital Management's FDMT Position: Q3 2026 in Review

Vanguard Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 2% in Q3 2026, buying an estimated $543K and bringing the position to 2,140,758 shares worth $30.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Vanguard Capital Management first reported a position in FDMT in Q1 2026 and has held it in 3 quarters since. 167 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Vanguard Capital Management held 2,140,758 shares of 4D Molecular Therapeutics worth $30.6M as of Q3 2026.
  • Vanguard Capital Management bought 41,703 4D Molecular Therapeutics shares in Q3 2026, an estimated $543K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2167 holding.
  • Vanguard Capital Management first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 167 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.